Tarveda to Present at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
-- Miniaturized size and unique design of Pentarins™ allow for rapid penetration deep into solid tumors to drive efficacy –-
WATERTOWN, MA, November 22, 2016 —Tarveda Therapeutics, Inc. a biopharmaceutical company discovering and developing Pentarins™ as a new class of potent and selective anti-cancer medicines, today announced that the company will present at the European Cancer Organization’s (ECCO) 28th EORTC-NCI-AACR Symposium, November 29 – December 2, at the Internationales Congress Center München (ICM), in Munich, Germany. The symposium, hosted by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI), and the American Association of Cancer Research (AACR), brings together academics, scientists, and industry representatives from across the globe to discuss the latest innovations in drug development, target selection and the impact of new discoveries in molecular biology.
Dr. Richard Wooster, President, Research & Development and Chief Scientific Officer, will give a podium presentation at the meeting on “Peptide Drug Conjugates: Developing Potent And Selective Miniaturized Conjugates For The Treatment Of Patients With Solid Tumors” as part of the “Why Antibody Drug Conjugates (ADC) Do Not Work” workshop. The presentation will take place on Wednesday, November 30, at 12:00 p.m. CET.
“Tarveda takes a novel approach to cancer therapeutics through our Pentarins™, which are potent and selective, miniaturized conjugates uniquely designed to penetrate deep into solid tumors, accumulate their payload, and cause cancer cell death,” said Dr. Wooster. “Due to their small size and innovative design, Pentarins are created through chemistry to address the deficits of larger ADCs, which have been hindered due to slow and limited penetration in solid tumors and payload dissociation resulting in target competition and toxicities of peripheral tissues. Pentarins have shown rapid penetration deep into solid tumor tissue and sustained regressions across a range of hard-to-treat cancer models.”
Pentarins are potent and selective miniaturized drug conjugates with high affinity for specific cell surface and intracellular targets and payload delivery deep into solid tumor tissue. Comprised of a targeting ligand conjugated to a potent cell-killing agent through a chemical linker, Pentarins are designed to overcome the deficits of larger antibody drug conjugates and small molecules that limit their therapeutic effectiveness against solid tumors. Together, the components of Tarveda’s Pentarins have distinct yet synergistic anticancer attributes: the small size of Pentarins allows for effective penetration and distribution into the tumor tissue, the ligand’s targeting ability allows for specific binding to tumor cells, the chemical linker is tuned to optimize the release of the potent, cell-killing payload inside the cancer cells for efficacy.
About Tarveda Therapeutics, Inc.
Tarveda Therapeutics, Inc., discovers and develops Pentarins™, a new class of potent and selective miniaturized drug conjugates with high-targeting capabilities for the treatment of solid cancer tumors. Tarveda’s lead Pentarin drug candidate, PEN-221, is a miniaturized biologic drug conjugate that targets the somatostatin receptor for treatment of patients with neuroendocrine and small cell lung cancers. Tarveda is also advancing its HSP90 drug conjugate platform with lead PEN-866, which is a miniaturized drug conjugate that comprises an HSP90 ligand conjugated to SN-38, the highly-potent, active metabolite of irinotecan. Tarveda’s strategy includes developing its own proprietary Pentarins as well as applying the Pentarin platform to enhance the effectiveness of the targeting moieties and novel payloads of pharmaceutical collaborators. www.tarveda.com